Stay updated on Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedPage updated from Revision: v3.0.2 to Revision: v3.2.0.SummaryDifference0.1%

- Check28 days agoChange DetectedVersion bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

- Check43 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2 and the 'Back to Top' link was removed. No substantive content changes were detected.SummaryDifference0.3%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.SummaryDifference0.3%

- Check57 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new drug names like pembrolizumab and amrubicin. However, many previously included resources and topics related to lung cancer have been removed.SummaryDifference4%

- Check71 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Amurubicin Combo in Refractory SCLC Clinical Trial page.